Table 1.
Th17-targeted drugs in clinical trials.
| Targeting Drug | Method of delivery | Disease Model | Phase | NCT code | Ref. | |
|---|---|---|---|---|---|---|
| IL-17 | MSB0010841 | s.c. | Psoriasis | I | NCT02156466 | (153) |
| Anti-IL-17A Humanized Monoclonal Antibody | s.c. | Psoriasis | II | NCT05604898 | (154) | |
| 608 Q2W | s.c. | Psoriasis | III | NCT05536726 | (154) | |
| JS005 | s.c. | Psoriasis | Ib/II | NCT05344248 | (155) | |
| BCD-085 | s.c. | Psoriasis | II | NCT02762994 | (156) | |
| LY2439821 | s.c. | Psoriasis | II | NCT01107457 | (157) | |
| AZD0284 | p.o. | Psoriasis | I | NCT03310320 | (158) | |
| CJM112 | s.c. | Psoriasis | I | NCT01828086 | (159) | |
| SHR-1314 | s.c. | Psoriasis | II | NCT04121143 | (160) | |
| Ixekizumab | s.c. | Lichen Planus | I | NCT05030415 | (161) | |
| IL-6 | Adalimumab | s.c. | Psoriasis | Not Applicable | NCT01320293 | (162) |
| Tocilizumab | p.o. | Behçet’s disease | II | NCT03554161 | (163) | |
| TA-650 | i.v. | Behçet’s disease | III | NCT01532570 | (164) | |
| IL-23 | LY2525623 | i.v. | Psoriasis | II | NCT01018810 | (165) |
| Risankizumab | s.c. | Psoriasis | IV | NCT04630652 | (166) | |
| Mirikizumab | s.c. | Psoriasis | III | NCT03535194 | (167) | |
| CNTO 1959 | s.c. | Palmoplantar Pustulosis | II | NCT01845987 | (168) | |
| LY3074828 | s.c. | Psoriasis | III | NCT03556202 | (169) | |
| CNTO 1275 | s.c. | Psoriasis | III | NCT00267969 | (170) | |
| Ustekinumab | s.c. | Behçet’s disease | II | NCT02648581 | (171) | |